HTG Molecular Diagnostics Inc (NASDAQ:HTGM)’s share price fell 4.2% on Tuesday . The stock traded as low as $2.45 and last traded at $2.49, with a volume of 375,537 shares trading hands. The stock had previously closed at $2.60.

Several brokerages recently weighed in on HTGM. Zacks Investment Research lowered shares of HTG Molecular Diagnostics from a “hold” rating to a “sell” rating in a research report on Monday, April 4th. Canaccord Genuity reissued a “buy” rating and issued a $10.00 price target on shares of HTG Molecular Diagnostics in a research report on Tuesday, March 22nd. Finally, Leerink Swann reissued an “outperform” rating and issued a $5.00 price target (down previously from $10.00) on shares of HTG Molecular Diagnostics in a research report on Monday, March 28th.

The stock’s market cap is $17.45 million. The company’s 50-day moving average price is $2.76 and its 200-day moving average price is $2.93.

HTG Molecular Diagnostics (NASDAQ:HTGM) last posted its earnings results on Thursday, May 12th. The company reported ($1.02) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.83) by $0.19. On average, equities research analysts forecast that HTG Molecular Diagnostics Inc will post ($3.91) EPS for the current year.

HTG Molecular Diagnostics, Inc is a provider of instruments and reagents for molecular profiling applications. The Company has developed and markets a technology platform for the routine use of complex molecular profiling. The Company’s HTG Edge platform, consisting of instrumentation, including HTG Edge and HTG EdgeSeq systems, consumables and software analytics, is used in sample profiling applications, including tumor profiling, molecular diagnostic testing and biomarker development.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.